Ep. 214 Ken Shreve: Improving Portfolio Health With Medical Stocks
Investing With IBD
00:00
Ion Endoluminal System
The R and D research and development, 53, uh, 0.8% on this one? That's pretty incredible. So you can kind of forgive the company for not being profitable because they're plowing a lot of that revenue into intoResearch and Development. The gap up on earnings, anytime a stock gaps up like intuitive surgical did and starts holding gains and, and trading sideways, means that the stock should be watched. It could just buy time underneath the 300 level here.
Transcript
Play full episode
